OPKO Health (NASDAQ:OPK) Shares Gap Up on Strong Earnings

OPKO Health, Inc. (NASDAQ:OPK) gapped up before the market opened on Tuesday following a better than expected earnings announcement. The stock had previously closed at $1.24, but opened at $1.38. OPKO Health shares last traded at $1.6340, with a volume of 8,172,413 shares changing hands.

The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.07. OPKO Health had a negative net margin of 36.63% and a negative return on equity of 16.78%. The company had revenue of $163.58 million during the quarter, compared to the consensus estimate of $131.23 million. During the same period in the prior year, the business earned ($0.19) earnings per share. The company’s revenue for the quarter was up 4.3% compared to the same quarter last year.

Key OPKO Health News

Here are the key news stories impacting OPKO Health this week:

• Positive Sentiment: OPKO reported a second-quarter loss of $0.01 per share, substantially better than the $0.08 loss analysts expected and the $0.19 loss recorded a year earlier. Revenue increased 4.3% year over year to $163.58 million, exceeding the $131.23 million consensus estimate. OPKO Health Reports Q2 Loss, Tops Revenue Estimates
• Positive Sentiment: Management raised its 2026 revenue guidance to $560 million-$585 million, above the approximately $536.4 million analyst consensus. The outlook implies continued growth from OPKO’s diagnostics and pharmaceutical businesses. OPKO 2026 Revenue Guidance
• Positive Sentiment: OPKO said its ModeX multispecific antibody programs generated data supporting plans to begin Phase 1 studies later this year or in early 2027. The company also expects to start clinical development of MDX3001 by the end of 2026 or early 2027, offering potential longer-term pipeline value. OPKO Second-Quarter Business Highlights
• Neutral Sentiment: Third-quarter revenue guidance of $131 million-$142 million brackets the $134.8 million consensus estimate, suggesting expectations are broadly intact but not significantly ahead of Wall Street forecasts.
• Negative Sentiment: Despite the quarterly beat, OPKO remains unprofitable, with a negative net margin of 36.63% and negative return on equity. The company’s full-year earnings outlook was not provided in the reported guidance, leaving investors focused on whether revenue growth can translate into improving profitability. OPKO Health Q2 Earnings Snapshot

Wall Street Analyst Weigh In

Several research firms recently commented on OPK. Barrington Research downgraded shares of OPKO Health from an “outperform” rating to a “market perform” rating in a research report on Wednesday, April 29th. Weiss Ratings upgraded shares of OPKO Health from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, May 18th. Finally, Wall Street Zen upgraded OPKO Health from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. Four equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Reduce” and a consensus price target of $1.55.

Institutional Trading of OPKO Health

A number of institutional investors have recently bought and sold shares of OPK. Goldman Sachs Group Inc. grew its holdings in OPKO Health by 150.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 5,986,913 shares of the biotechnology company’s stock worth $7,544,000 after acquiring an additional 3,600,378 shares during the period. Millennium Management LLC grew its stake in OPKO Health by 39.2% during the first quarter. Millennium Management LLC now owns 6,386,911 shares of the biotechnology company’s stock worth $10,602,000 after purchasing an additional 1,798,385 shares during the period. AQR Capital Management LLC increased its holdings in OPKO Health by 466.7% in the first quarter. AQR Capital Management LLC now owns 1,608,906 shares of the biotechnology company’s stock worth $2,671,000 after purchasing an additional 1,324,988 shares in the last quarter. OP Asset Management Ltd acquired a new position in OPKO Health in the first quarter valued at approximately $1,257,000. Finally, HRT Financial LP acquired a new stake in shares of OPKO Health during the 4th quarter worth approximately $851,000. Institutional investors own 64.63% of the company’s stock.

OPKO Health Price Performance

The company has a debt-to-equity ratio of 0.28, a current ratio of 3.61 and a quick ratio of 3.17. The firm has a market capitalization of $1.21 billion, a price-to-earnings ratio of -5.91 and a beta of 1.48. The business’s fifty day simple moving average is $1.37 and its 200 day simple moving average is $1.26.

OPKO Health Company Profile

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.